Shilpa Medicare Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 5, 2025, 5:18 pm

Quick Insight

Shilpa Medicare Ltd, within the pharmaceutical industry, currently trades at a price of 817 with a market capitalization of 7,987 Cr. The company's P/E stands at 62.1, reflecting a high valuation compared to its industry peers. Despite this, the ROE and ROCE figures of 4.28% and 7.94% respectively indicate a lower profitability efficiency. A positive OPM of 28% is a bright spot, yet the net profit of 78 Cr may raise concerns. With reserves at 2,362 Cr and borrowings of ₹588 Cr, the company's financial health appears stable, although a CCC of 350 days warrants attention. The P/BV ratio of 2.73x and ICR of 4.50x suggest a reasonable valuation and debt coverage. Overall, while Shilpa Medicare shows potential, investors should closely monitor its operational efficiency and profitability metrics for sustained growth.

Competitors of Shilpa Medicare Ltd

All Competitor Stocks of Shilpa Medicare Ltd

Quarterly Result

Last Updated: August 20, 2025, 3:50 am

Below is a detailed analysis of the quarterly data for Shilpa Medicare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 321.00 Cr.. The value appears to be declining and may need further review. It has decreased from 331.00 Cr. (Mar 2025) to 321.00 Cr., marking a decrease of 10.00 Cr..
• For Expenses, as of Jun 2025, the value is 231.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 254.00 Cr. (Mar 2025) to 231.00 Cr., marking a decrease of 23.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 91.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Mar 2025) to 91.00 Cr., marking an increase of 14.00 Cr..
• For OPM %, as of Jun 2025, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 28.00%, marking an increase of 5.00%.
• For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from -18.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 24.00 Cr..
• For Interest, as of Jun 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 5.00 Cr..
• For Depreciation, as of Jun 2025, the value is 29.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 29.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 35.00 Cr..
• For Tax %, as of Jun 2025, the value is 5.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00%.
• For Net Profit, as of Jun 2025, the value is 47.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Mar 2025) to 47.00 Cr., marking an increase of 32.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 4.79. The value appears strong and on an upward trend. It has increased from 1.48 (Mar 2025) to 4.79, marking an increase of 3.31.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 2:06 pm

Growth

Last Updated: September 5, 2025, 1:26 pm

Balance Sheet

Last Updated: June 16, 2025, 11:22 am

Below is a detailed analysis of the balance sheet data for Shilpa Medicare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2024) to 10.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 2,362.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,800.00 Cr. (Mar 2024) to 2,362.00 Cr., marking an increase of 562.00 Cr..
• For Borrowings, as of Mar 2025, the value is 588.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 937.00 Cr. (Mar 2024) to 588.00 Cr., marking a decrease of 349.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 351.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 347.00 Cr. (Mar 2024) to 351.00 Cr., marking an increase of 4.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 3,311.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,093.00 Cr. (Mar 2024) to 3,311.00 Cr., marking an increase of 218.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1,777.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,385.00 Cr. (Mar 2024) to 1,777.00 Cr., marking an increase of 392.00 Cr..
• For CWIP, as of Mar 2025, the value is 463.00 Cr.. The value appears to be declining and may need further review. It has decreased from 719.00 Cr. (Mar 2024) to 463.00 Cr., marking a decrease of 256.00 Cr..
• For Investments, as of Mar 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2024) to 35.00 Cr., marking a decrease of 5.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,037.00 Cr.. The value appears strong and on an upward trend. It has increased from 950.00 Cr. (Mar 2024) to 1,037.00 Cr., marking an increase of 87.00 Cr..
• For Total Assets, as of Mar 2025, the value is 3,311.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,093.00 Cr. (Mar 2024) to 3,311.00 Cr., marking an increase of 218.00 Cr..

Notably, the Reserves (2,362.00 Cr.) exceed the Borrowings (588.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Shilpa Medicare Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 8.04. This value is within the healthy range. It has increased from 3.67 (Mar 24) to 8.04, marking an increase of 4.37.
• For Diluted EPS (Rs.), as of Mar 25, the value is 8.04. This value is within the healthy range. It has increased from 3.67 (Mar 24) to 8.04, marking an increase of 4.37.
• For Cash EPS (Rs.), as of Mar 25, the value is 19.70. This value is within the healthy range. It has increased from 16.66 (Mar 24) to 19.70, marking an increase of 3.04.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 242.65. It has increased from 208.37 (Mar 24) to 242.65, marking an increase of 34.28.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 242.65. It has increased from 208.37 (Mar 24) to 242.65, marking an increase of 34.28.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 131.59. It has decreased from 132.67 (Mar 24) to 131.59, marking a decrease of 1.08.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 34.80. This value is within the healthy range. It has increased from 29.11 (Mar 24) to 34.80, marking an increase of 5.69.
• For PBIT / Share (Rs.), as of Mar 25, the value is 23.24. This value is within the healthy range. It has increased from 16.68 (Mar 24) to 23.24, marking an increase of 6.56.
• For PBT / Share (Rs.), as of Mar 25, the value is 12.64. This value is within the healthy range. It has increased from 6.81 (Mar 24) to 12.64, marking an increase of 5.83.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 8.14. This value is within the healthy range. It has increased from 4.23 (Mar 24) to 8.14, marking an increase of 3.91.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.01. This value is within the healthy range. It has increased from 3.67 (Mar 24) to 8.01, marking an increase of 4.34.
• For PBDIT Margin (%), as of Mar 25, the value is 26.44. This value is within the healthy range. It has increased from 21.94 (Mar 24) to 26.44, marking an increase of 4.50.
• For PBIT Margin (%), as of Mar 25, the value is 17.66. This value is within the healthy range. It has increased from 12.57 (Mar 24) to 17.66, marking an increase of 5.09.
• For PBT Margin (%), as of Mar 25, the value is 9.60. This value is below the healthy minimum of 10. It has increased from 5.13 (Mar 24) to 9.60, marking an increase of 4.47.
• For Net Profit Margin (%), as of Mar 25, the value is 6.18. This value is within the healthy range. It has increased from 3.18 (Mar 24) to 6.18, marking an increase of 3.00.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.08. This value is below the healthy minimum of 8. It has increased from 2.76 (Mar 24) to 6.08, marking an increase of 3.32.
• For Return on Networth / Equity (%), as of Mar 25, the value is 3.30. This value is below the healthy minimum of 15. It has increased from 1.76 (Mar 24) to 3.30, marking an increase of 1.54.
• For Return on Capital Employeed (%), as of Mar 25, the value is 8.61. This value is below the healthy minimum of 10. It has increased from 6.03 (Mar 24) to 8.61, marking an increase of 2.58.
• For Return On Assets (%), as of Mar 25, the value is 2.36. This value is below the healthy minimum of 5. It has increased from 1.03 (Mar 24) to 2.36, marking an increase of 1.33.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.30 (Mar 24) to 0.09, marking a decrease of 0.21.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.24. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.24, marking a decrease of 0.27.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has increased from 0.38 (Mar 24) to 0.40, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has increased from 1.26 (Mar 24) to 1.46, marking an increase of 0.20.
• For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.94, marking an increase of 0.18.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.01. This value is below the healthy minimum of 4. It has decreased from 1.28 (Mar 24) to 1.01, marking a decrease of 0.27.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 4.50. This value is within the healthy range. It has increased from 2.75 (Mar 24) to 4.50, marking an increase of 1.75.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 3. It has increased from 1.33 (Mar 24) to 2.43, marking an increase of 1.10.
• For Enterprise Value (Cr.), as of Mar 25, the value is 7,030.92. It has increased from 4,901.02 (Mar 24) to 7,030.92, marking an increase of 2,129.90.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.47. This value exceeds the healthy maximum of 3. It has increased from 4.26 (Mar 24) to 5.47, marking an increase of 1.21.
• For EV / EBITDA (X), as of Mar 25, the value is 20.67. This value exceeds the healthy maximum of 15. It has increased from 19.40 (Mar 24) to 20.67, marking an increase of 1.27.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.04. This value exceeds the healthy maximum of 3. It has increased from 3.48 (Mar 24) to 5.04, marking an increase of 1.56.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 2.73. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.73, marking an increase of 0.52.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.04. This value exceeds the healthy maximum of 3. It has increased from 3.48 (Mar 24) to 5.04, marking an increase of 1.56.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness